Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 168)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Thrombin |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
coagulation factor II
THROMBIN
Thrombin bovine
|
Thrombin, Topical (Bovine)
THROMBOSTAT
|
|
2 |
|
Tranexamic acid |
Approved |
Phase 4 |
|
1197-18-8 |
5526 |
Synonyms:
(1R,4R)-4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID
Acide tranexamique
Acide tranéxamique
Acido tranexamico
ácido tranexámico
Acidum tranexamicum
CL-65336
CL-65336|Cyclo-F®|Cyklokapron®|Femstrual®|trans AMCHA
CYCLO-F
CYKLO-F HEAVY PERIOD RELIEF
Cyklokapron
EXACYL
FEMSTRUAL
LB1148
LB-1148
LYSTEDA
MENSTRALITE
|
NSC-291305
RP-18429
Tranexamate
Tranexamic acid
Tranexamsaeure
Tranexmate
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
trans-Tranexamate
trans-Tranexamic acid
|
|
3 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
4 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
5 |
|
Prilocaine |
Approved |
Phase 4 |
|
721-50-6 |
4906 |
Synonyms:
2-(Propylamino)-O-propionotoluidide
2-Methyl-alpha-propylaminopropionanilide
2-Methyl-a-propylaminopropionanilide
2-Methyl-α-propylaminopropionanilide
alpha-N-Propylamino-2-methylpropionanilide
a-N-Propylamino-2-methylpropionanilide
ASTRA 1512
Astra 1515
Astra brand OF prilocaine hydrochloride
ASTRA-1512
ASTRA-1515
AstraZeneca brand OF prilocaine hydrochloride
Citanest
Citanest octapressin
Citanest Plain
Delvet brand OF prilocaine hydrochloride
Inibsa brand OF prilocaine hydrochloride
L-67
|
N-(2-Methylphenyl)-2-(propylamino)propanamide
NSC-40027
O-Methyl-2-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
O-Methyl-a-propylaminopropionanilide
O-Methyl-α-propylaminopropionanilide
Parnell brand OF prilocaine hydrochloride
PRILOCAIN
Prilocaina
PRILOCAINE
PRILOCAÏNE
Prilocaine base
Prilocaine hydrochloride
Prilocainum
PRILOTEKAL
Propitocaine
Xylonest
Α-N-propylamino-2-methylpropionanilide
|
|
6 |
|
Fibrin Tissue Adhesive |
|
Phase 4 |
|
|
|
7 |
|
Antifibrinolytic Agents |
|
Phase 4 |
|
|
|
8 |
|
Hemostatics |
|
Phase 4 |
|
|
|
9 |
|
Coagulants |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
11 |
|
Anesthetics |
|
Phase 4 |
|
|
|
12 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
13 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
14 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
15 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
16 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
17 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
20 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
21 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
22 |
|
Mydriatics |
|
Phase 4 |
|
|
|
23 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
24 |
|
Progesterone |
Approved, Vet_approved |
Phase 3 |
|
57-83-0 |
5994 |
Synonyms:
(1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
(8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(S)-4-PREGNENE-3,20-DIONE
(S)-PREGN-4-EN-3,20-DIONE
(S)-PROGESTERONE
17ALPHA-PROGESTERONE
17A-PROGESTERONE
17Α-PROGESTERONE
3,20-PREGNENE-4
4-PREGNEN-3,20-DIONE
4-PREGNENE-3,20-DIONE
AGOLUTIN
AKROLUTIN
Amen
BETA-PROGESTERONE
BIO-LUTON
CIDR
COLPROSTERONE
CORLUTIN
CORLUTINA
CORLUVITE
CORPORIN
CORPUS LUTEUM HORMONE
CRINONE
CRINONE PROGESTERONE GEL
CURRETAB
CYCLOGEST
CYCLOGESTERIN
Cycrin
D4-PREGNENE-3,20-DIONE
DELALUTIN
DELTA(4)-PREGNENE-3,20-DIONE
DELTA(SUP 4)-PREGNENE-3,20-DIONE
DURAPROGEN
ENDOMETRIN
ESTIMA
FLAVOLUTAN
FOLOGENON
Gelbkoerperhormon
GELBKÖRPERHORMON
GESTEROL
GESTEROL 100
GESTEROL 50
GESTIRON
GESTONE
GESTORMONE
GESTRON
GLANDUCORPIN
GYNLUTIN
GYNOLUTON
GYNOLUTONE
HORMOFLAVEINE
HORMOLUTON
Hydroxyprogesterone caproate
Hydroxyprogesterone caproic acid
LINGUSORBS
LIPO-LUTIN
LUCORTEUM
LUCORTEUM SOL
LUGESTERON
LUTEAL HORMONE
Luteinique
LUTEOCRIN NORMALE
LUTEODYN
LUTEOGAN
LUTEOHORMONE
LUTEOL
LUTEOPUR
LUTEOSAN
LUTEOSTAB
LUTEOVIS
LUTEUM
LUTEX
LUTIDON
LUTIGEST
|
Lutin
LUTOCICLINA
LUTOCUCLIN M
LUTOCYCLIN
LUTOCYCLIN M
LUTOCYLIN
LUTOCYLOL
LUTOFORM
LUTOGYL
LUTOGYNON
LUTREN
LUTROMONE
MEMBRETTES
METHYLPREGNONE
MPA
NALUTRON
NSC-64377
NSC-9704
PERCUTACRINE
PERCUTACRINE LUTEINIQUE
PIAPONON
PRANONE
PREGN-4-EN-3,20-DIONE
PREGN-4-ENE-3,20-DIONE
PREGNENE-3,20-DIONE
PREGNENEDIONE
PRIMOLUT
PROCHIEVE
PROGEFFIK
PROGEKAN
PROGESTA-CARE
PROGESTAN
PROGESTASERT
PROGESTEROL
PROGESTERON
PROGESTERONA
Progesterona [INN-Spanish]
PROGESTERONE
PROGESTÉRONE
Progesterone, (13 alpha,17 alpha)-(+-)-isomer
Progesterone, (17 alpha)-isomer
Progesterone, (9 beta,10 alpha)-isomer
PROGESTERONUM
Progesteronum [INN-Latin]
PROGESTIN
PROGESTOGEL
PROGESTOL
PROGESTON
PROGESTONE
PROGESTOSOL
PROGESTRON
PROGESTRONOL
PROJESTAJECT
PROLETS
PROLIDON
PROLUTIN
PROLUTON
PROLUTONE
PROMETRIUM
Prometrium®|Utrogestan®
PRONTOGEST
PROTORMONE
REGUMATE
SERENITY FOR WOMEN
SYNGESTERONE
SYNGESTRETS
SYNGESTRONE
SYNOVEX S
SYNTOLUTAN
Thiuram E
Thiuranide
U 3672
UTROGEST
UTROGESTAN
VITARRINE
Δ(4)-pregnene-3,20-dione
|
|
25 |
|
Mifepristone |
Approved, Investigational |
Phase 3 |
|
84371-65-3 |
55245 |
Synonyms:
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
Contragest brand OF mifepristone
Corlux
Danco brand OF mifepristone
Exelgyn brand OF mifepristone
Korlym
Mifegyne
Mifégyne
Mifeprex
Mifeprex®|RU-486|RU486
Mifepriston
|
Mifepristona
Mifepristone
Mifépristone
Mifepristone contragest brand
Mifepristone danco brand
Mifepristone exelgyn brand
Mifepristonum
RU-38486
RU486
RU-486
|
|
26 |
|
Cisatracurium |
Approved, Investigational |
Phase 3 |
|
96946-41-7 |
62887 |
Synonyms:
(1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
(1R,2R,1'r,2'r)-Atracurium
(1R-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
(1R-cis,1'r-cis)-Atracurium
CISATRACURIUM
|
Cisatracurium besilate
Cisatracurium besylate
Cisatracurium cation
Cisatracurium ion
Nimbex
|
|
27 |
|
Magnesium sulfate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
7487-88-9 |
|
Synonyms:
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulphate
|
magnesium(II) sulfate
Magnesiumsulfat
MgSO4
|
|
28 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 3 |
|
28523-86-6 |
5206 |
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Fluoromethyl hexafluoroisopropyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
HFE-347MMZ1
MR6S4
MR-6S4
Sevofluran
SEVOFLURANE
|
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevorane
SOJOURN
Ultane
|
|
29 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
ABSTRAL
Abstral®|Actiq®|Durogesic®|Effentora®|MCN-JR-4263-49|R-4263|Sublimaze®
ACTIQ
AD 923
AD-923
BREAKYL
Cephalon brand OF fentanyl buccal oravescent
Duragesic
DURAGESIC-100
DURAGESIC-12
DURAGESIC-25
DURAGESIC-37
DURAGESIC-50
DURAGESIC-75
Durogesic
DUROGESIC DTRANS
EFFENTORA
FENCINO
FENTALIS RESERVOIR
Fentanest
Fentanil
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl CII
Fentanyl citrate
FENTANYL-100
FENTANYL-12
FENTANYL-25
FENTANYL-37
FENTANYL-50
FENTANYL-62
FENTANYL-75
FENTANYL-87
Fentanylum
|
Fentanylum [INN-Latin]
Fentora
IDS-NF-001
INNOVAR
IONSYS
Janssen pharmaceutica brand OF fentanyl
LEPTANAL
MATRIFEN
MCN-JR-4263-49
MEZOLAR MATRIX
MYLAFENT
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N02AB03
Nasalfent
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
OPIODUR
ORALET
OSMACH
OSMANIL
PECFENT
Pentanyl
Phentanyl
R 4263
R-4263
Rapinyl
RECIVIT
Sentonil
Sublimaze
Subsys
TILOFYL
Transmucosal oral fentanyl citrate
VICTANYL
YEMEX
|
|
30 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 3 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
31 |
|
Aminolevulinic acid |
Approved |
Phase 3 |
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
32 |
|
Hormones |
|
Phase 3 |
|
|
|
33 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
34 |
|
glucocorticoids |
|
Phase 3 |
|
|
|
35 |
|
Contraceptives, Postcoital |
|
Phase 3 |
|
|
|
36 |
|
Contraceptives, Oral |
|
Phase 3 |
|
|
|
37 |
|
Contraceptive Agents |
|
Phase 3 |
|
|
|
38 |
|
Progestins |
|
Phase 3 |
|
|
|
39 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
40 |
|
Photosensitizing Agents |
|
Phase 3 |
|
|
|
41 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
42 |
|
Erlotinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
43 |
|
Aldesleukin |
Approved |
Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
44 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
45 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
46 |
|
Hydroxyurea |
Approved |
Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
47 |
|
Copper |
Approved, Investigational |
Phase 1, Phase 2 |
|
7440-50-8 |
27099 |
Synonyms:
cobre
COPPER (II) ion
Copper(II) cation
Copper, ion (cu2+)
Cu
Cu(2+)
|
Cu(II)
Cu2+
cuivre
Cupric ion
cuprum
Kupfer
|
|
48 |
|
Trabectedin |
Approved, Investigational |
Phase 2 |
|
114899-77-3 |
108150 |
Synonyms:
Ect 743
Ecteinascidin
Ecteinascidin 743
ecteinascidin 743|ET-743|Yondelis®
ECTEINASCIDINS TRABECTEDIN
ET743
|
ET-743
NSC 684766
NSC-648766
Trabectedin
Trabectedina
Yondelis
|
|
49 |
|
Verapamil |
Approved |
Phase 2 |
|
152-11-4, 52-53-9 |
2520 |
Synonyms:
Akilen
Anpec
ANSYR
Ansyr®|CP-165331 / CP-16533-1|Securon®
Apo-verap
Arpamyl
Arpamyl LP
BERKATENS
CALAN
CALAN SR
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor retard
Coraver
CORDILOX
CORDILOX I.V.
CORDILOX MR 240
Cordilox SR
Corpamil
COVERA
COVERA-HS
CP-165331
CP-16533-1
CP-165331 / CP-16533-1
CP-16533-1Calan
CP-165331Verapamil
D-365
D-365Iproveratril
delta-365
Dexverapamil
Dignover
Dilacoran
Dilacoran hta
Drosteakard
Durasoptin
Elthon
ETHIMIL MR 240
Falicard
Finoptin
Flamon
GEANGIN
HALF SECURON SR
Harteze
Hexasoptin
Hexasoptin retard
Hormitol
Hydrochloride, verapamil
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
ISOPTIN
Isoptin retard
ISOPTIN SR
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
Lekoptin
Lodixal
LU-20175
Magotiron
Manidon
Manidon retard
MANIDON SR
Novapamyl LP
Novo-veramil
|
NSC-272306NA
NSC-272366
NSC-657799
Nu-verap
Ormil
Praecicor
Quasar
RANVERA MR
Rapam
Robatelan
Sandoz brand OF verapamil
SECURON
SECURON IV
SECURON MID
SECURON SR
Tarka
UNIVER
Univex
Vasolan
Vasomil
Vasopten
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Vérapamil
Verapamil [Usan:Ban:Inn]
Verapamil acis
Verapamil al
Verapamil atid
Verapamil basics
Verapamil ebewe
VERAPAMIL HCL
Verapamil henning
Verapamil hydrochloride
Verapamil injection
Verapamil MSD
Verapamil NM
Verapamil NM pharma
Verapamil nordic
Verapamil PB
Verapamil riker
Verapamil sandoz brand
Verapamil SR
Verapamil verla
Verapamil-abz
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
VERAPRESS MR 240
Veraptin
Verasal
Vera-sanorania
Verasifar
Veratensin
VERA-TIL SR
Verdilac
VERELAN
VERELAN PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
VERTAB SR 240
Vetrimil
Vortac
ZOLVERA
|
|
50 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
Interventional clinical trials:
(show top 50)
(show all 158)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. |
Unknown status |
NCT03190122 |
Phase 4 |
|
2 |
Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial |
Unknown status |
NCT02863484 |
Phase 4 |
|
3 |
A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery |
Completed |
NCT02034799 |
Phase 4 |
|
4 |
Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study |
Not yet recruiting |
NCT04386642 |
Phase 4 |
Tranexamic acid;Placebo |
5 |
Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction |
Not yet recruiting |
NCT04756050 |
Phase 4 |
Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg |
6 |
Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial |
Unknown status |
NCT00517959 |
Phase 3 |
|
7 |
PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS |
Unknown status |
NCT01655927 |
Phase 3 |
Tranexamic Acid;Placebo: Saline |
8 |
Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma |
Completed |
NCT03015701 |
Phase 3 |
Mifepristone |
9 |
The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal |
Completed |
NCT03558516 |
Phase 3 |
Magnesium group;Normal saline group |
10 |
Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE |
Completed |
NCT02947984 |
Phase 3 |
|
11 |
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma |
Recruiting |
NCT03180268 |
Phase 3 |
|
12 |
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas |
Recruiting |
NCT04305470 |
Phase 3 |
Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI) |
13 |
A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas |
Recruiting |
NCT05130866 |
Phase 2, Phase 3 |
REC-2282;Placebo |
14 |
Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study |
Terminated |
NCT00104936 |
Phase 3 |
|
15 |
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma |
Unknown status |
NCT03016091 |
Phase 2 |
Pembrolizumab |
16 |
IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study |
Unknown status |
NCT00904735 |
Phase 2 |
hydroxyurea;imatinib mesylate |
17 |
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. |
Unknown status |
NCT02333565 |
Phase 2 |
Everolimus;Octreotide |
18 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
19 |
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas |
Completed |
NCT01125046 |
Phase 2 |
|
20 |
Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma |
Completed |
NCT00045734 |
Phase 2 |
imatinib mesylate |
21 |
A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy |
Completed |
NCT00045110 |
Phase 1, Phase 2 |
erlotinib hydrochloride |
22 |
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors |
Completed |
NCT00004078 |
Phase 2 |
irinotecan hydrochloride |
23 |
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma |
Completed |
NCT00859040 |
Phase 2 |
SOM230C |
24 |
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma |
Completed |
NCT00589784 |
Phase 2 |
Sunitinib |
25 |
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs |
Completed |
NCT00025675 |
Phase 2 |
gefitinib |
26 |
Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma |
Completed |
NCT00006119 |
Phase 2 |
hydroxyurea |
27 |
Phase II Study of Hydroxyurea for Unresectable Meningioma |
Completed |
NCT00003590 |
Phase 2 |
hydroxyurea |
28 |
A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma |
Completed |
NCT00354913 |
Phase 2 |
hydroxyurea;imatinib mesylate |
29 |
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEâ„¢: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial |
Completed |
NCT03936426 |
Phase 1, Phase 2 |
Cu-64 SARTATE and Cu-67 SARTATE |
30 |
Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group |
Completed |
NCT02234050 |
Phase 2 |
Trabectedin |
31 |
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas |
Completed |
NCT00706810 |
Phase 2 |
Hydroxyurea;Verapamil |
32 |
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes |
Completed |
NCT01967823 |
Phase 2 |
Cyclophosphamide;Fludarabine;Aldesleukin |
33 |
Proton Radiation for Low Grade Gliomas |
Completed |
NCT01024907 |
Phase 1, Phase 2 |
|
34 |
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas |
Completed |
NCT02831257 |
Phase 2 |
AZD2014 |
35 |
Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas |
Completed |
NCT00002965 |
Phase 2 |
|
36 |
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas |
Completed |
NCT00010049 |
Phase 1, Phase 2 |
imatinib mesylate |
37 |
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas |
Completed |
NCT00348790 |
Phase 2 |
vatalanib |
38 |
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma |
Recruiting |
NCT02847559 |
Phase 2 |
|
39 |
A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy |
Recruiting |
NCT04082520 |
Phase 2 |
Lutetium Lu 177 Dotatate |
40 |
A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma |
Recruiting |
NCT04659811 |
Phase 2 |
Pembrolizumab |
41 |
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma |
Recruiting |
NCT03604978 |
Phase 1, Phase 2 |
|
42 |
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations |
Recruiting |
NCT02523014 |
Phase 2 |
Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib |
43 |
SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC |
Recruiting |
NCT04298541 |
Phase 2 |
Ga-68- DOTATATE;Ga-68-DOTATOC |
44 |
An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma |
Recruiting |
NCT02648997 |
Phase 2 |
Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg |
45 |
A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma |
Recruiting |
NCT03971461 |
Phase 2 |
Lutathera |
46 |
An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma |
Recruiting |
NCT05023018 |
Phase 2 |
NEO100 |
47 |
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma |
Recruiting |
NCT05425004 |
Phase 2 |
Cabozantinib |
48 |
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) |
Recruiting |
NCT04374305 |
Phase 2 |
Brigatinib;Neratinib |
49 |
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
Recruiting |
NCT03095248 |
Phase 2 |
Selumetinib |
50 |
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers |
Recruiting |
NCT03173950 |
Phase 2 |
Nivolumab |
|